Novo May Have Muscle Advantage over Lilly in Weight-Loss Race: Preprint

Why It Matters

Preserving lean muscle while achieving weight loss is a key differentiator for obesity therapies, potentially shifting prescriber preference toward semaglutide and influencing market dynamics between Novo and Lilly.

Key Takeaways

• Semaglutide showed 6.7% depletive metabotype vs 10.3% for tirzepatide.
• Tirzepatide patients lost 57% more total weight than semaglutide group.
• Higher GLP‑1 doses linked to greater lean‑mass loss in both drugs.
• Study is observational pre‑print, not yet peer‑reviewed.
• Lean‑mass preservation could give Novo a market edge if confirmed.

Pulse Analysis

The observational analysis, posted on medRxiv, examined body‑composition data from almost 8,000 patients initiating GLP‑1 therapy. Researchers classified outcomes into two metabotypes: a depletive profile with >20% total weight loss and >5% lean‑mass loss, and a prime profile with >10% weight loss but <5% lean‑mass loss. Semaglutide patients were less likely to enter the depletive category (6.7%) than tirzepatide patients (10.3%), even though tirzepatide achieved 57% greater overall weight reduction. Dose intensity and treatment duration amplified lean‑mass loss for both agents, underscoring the trade‑off between efficacy and muscle preservation.

Clinicians and payers watch body‑composition metrics closely, as excessive lean‑mass loss can impair metabolic health and functional capacity. While tirzepatide’s superior weight‑loss numbers have driven strong sales, the emerging evidence that semaglutide better spares muscle may reposition it as the preferred option for patients at risk of sarcopenia or frailty. However, the study’s retrospective design and lack of peer review limit definitive conclusions. Prospective head‑to‑head trials will be essential to validate these findings and to guide labeling, dosing strategies, and reimbursement decisions.

The broader market context intensifies the stakes. Lilly’s newly approved oral pill, Foundayo, faces FDA‑cited cardiovascular and liver safety concerns, while Novo’s oral Wegovy enjoys a launch lead. Simultaneously, Merck’s Keytruda is poised to lose exclusivity, shifting investor focus toward high‑growth GLP‑1 franchises. If semaglutide can substantiate a lean‑mass advantage, Novo may close the commercial gap with Lilly, reinforcing its dominance in the multi‑billion‑dollar obesity‑treatment segment.